I-DXd not checked
Merck & Co. · DS-7300a · MK-2400
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lung Neoplasm, Oesophageal Squamous Cell Carcinoma, Small Cell Lung Cancer Extensive Stage, Esophageal Squamous Cell Carcinoma
- Main trialPhase 2
- “Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may…”In the company’s words, NCT06780098 on ClinicalTrials.gov
- Other names
- Ifinatamab Deruxtecan · DS-7300a · MK-2400
Other drugs for Lung Neoplasm
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up4
- 12 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 29 Nov 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 4 Jan 2032Phase 1/2 trial completes · ClinicalTrials.gov
- 2 Mar 2032Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 2 Mar 2032 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | |
| Phase 1/2Recruiting | 12 Jun 2027 | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | |
| Phase 1/2Recruiting | 29 Nov 2030 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | |
| Phase 1/2Recruiting | 4 Jan 2032 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026